Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials.

Eichenauer DA, Becker I, Monsef I, Chadwick N, de Sanctis V, Federico M, Fortpied C, Gianni AM, Henry-Amar M, Hoskin P, Johnson P, Luminari S, Bellei M, Pulsoni A, Sydes MR, Valagussa P, Viviani S, Engert A, Franklin J.

Haematologica. 2017 Oct;102(10):1748-1757. doi: 10.3324/haematol.2017.167478. Epub 2017 Sep 14.

2.

Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience.

Ali S, Basit A, Kazmi AS, Sidhu A, Badar F, Hameed A.

Pak J Med Sci. 2016 Nov-Dec;32(6):1408-1413. doi: 10.12669/pjms.326.11080.

3.

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH.

Blood. 2016 Sep 15;128(11):1458-64. doi: 10.1182/blood-2016-03-703470. Epub 2016 Jul 25.

4.

Pembrolizumab in classical Hodgkin's lymphoma.

Maly J, Alinari L.

Eur J Haematol. 2016 Sep;97(3):219-27. doi: 10.1111/ejh.12770. Epub 2016 May 30. Review.

5.

Prognostic Implication of the Absolute Lymphocyte to Absolute Monocyte Count Ratio in Patients With Classical Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine or Equivalent Regimens.

Vassilakopoulos TP, Dimopoulou MN, Angelopoulou MK, Petevi K, Pangalis GA, Moschogiannis M, Dimou M, Boutsikas G, Kanellopoulos A, Gainaru G, Plata E, Flevari P, Koutsi K, Papageorgiou L, Telonis V, Tsaftaridis P, Sachanas S, Yiakoumis X, Tsirkinidis P, Viniou NA, Siakantaris MP, Variami E, Kyrtsonis MC, Meletis J, Panayiotidis P, Konstantopoulos K.

Oncologist. 2016 Mar;21(3):343-53. doi: 10.1634/theoncologist.2015-0251. Epub 2016 Feb 26.

6.

SEOM clinical guidelines for the treatment of Hodgkin's lymphoma.

Rueda Domínguez A, Alfaro Lizaso J, de la Cruz Merino L, Gumá I Padró J, Quero Blanco C, Gómez Codina J, Llanos Muñoz M, Martinez Banaclocha N, Rodriguez Abreu D, Provencio Pulla M.

Clin Transl Oncol. 2015 Dec;17(12):1005-13. doi: 10.1007/s12094-015-1429-1. Epub 2015 Oct 26.

7.

Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival.

Parikh RR, Grossbard ML, Harrison LB, Yahalom J.

Leuk Lymphoma. 2015 Oct 2:1-8. [Epub ahead of print]

8.

Hodgkin lymphoma, version 2.2015.

Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Tsien C, Winter JN, Yahalom J, Burns JL, Sundar H; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 May;13(5):554-86.

9.

Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.

Gandikota N, Hartridge-Lambert S, Migliacci JC, Yahalom J, Portlock CS, Schöder H.

Cancer. 2015 Jun 15;121(12):1985-92. doi: 10.1002/cncr.29277. Epub 2015 Mar 4.

10.

Risk of second malignancies in patients with early-stage classical Hodgkin's lymphoma treated in a modern era.

LeMieux MH, Solanki AA, Mahmood U, Chmura SJ, Koshy M.

Cancer Med. 2015 Apr;4(4):513-8. doi: 10.1002/cam4.405. Epub 2015 Jan 26.

11.

The Evolving Role of Radiotherapy in Early Stage Hodgkin's Lymphoma.

Ricardi U, Filippi AR, Piva C, Franco P.

Mediterr J Hematol Infect Dis. 2014 Jun 1;6(1):e2014035. doi: 10.4084/MJHID.2014.035. eCollection 2014. Review.

12.
14.

The role of fluorodeoxyglucose positron emission tomography-computerized tomography in resolving therapeutic dilemmas in pediatric Hodgkin lymphoma.

Seth R, Puri K, Singh P, Selvam P, Kumar R.

Indian J Nucl Med. 2012 Jul;27(3):141-4. doi: 10.4103/0972-3919.112717.

15.

Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease.

Antoni D, Natarajan-Ame S, Meyer P, Niederst C, Bourahla K, Noel G.

Radiat Oncol. 2013 May 2;8:112. doi: 10.1186/1748-717X-8-112.

16.

Hodgkin's lymphoma in adults: diagnosis, treatment and follow-up.

Rancea M, Engert A, von Tresckow B, Halbsguth T, Behringer K, Skoetz N.

Dtsch Arztebl Int. 2013 Mar;110(11):177-83, 183e1-3. doi: 10.3238/arztebl.2013.0177. Epub 2013 Mar 15.

17.

Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial.

Advani RH, Hoppe RT, Baer D, Mason J, Warnke R, Allen J, Daadi S, Rosenberg SA, Horning SJ.

Ann Oncol. 2013 Apr;24(4):1044-8. doi: 10.1093/annonc/mds542. Epub 2012 Nov 7.

18.

Hodgkin lymphoma.

Küppers R, Engert A, Hansmann ML.

J Clin Invest. 2012 Oct;122(10):3439-47. doi: 10.1172/JCI61245. Epub 2012 Oct 1. Review.

19.

Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis.

Aquino S, Clavio M, Rossi E, Vignolo L, Miglino M, Spriano M, Canepa L, Catania G, Pierri I, Bergamaschi M, Gonella R, Marani C, Racchi O, Cavaliere M, Goretti R, Carbone F, Bruzzone A, Tassara R, Carella AM, Ghio R, Gobbi M.

Oncol Lett. 2011 Mar;2(2):289-295. Epub 2011 Jan 21.

20.

Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.

Meyer RM, Hoppe RT.

Blood. 2012 Nov 29;120(23):4488-95. doi: 10.1182/blood-2012-05-423236. Epub 2012 Jul 20. Review.

Supplemental Content

Support Center